Show simple item record

dc.contributor.authorChamcha, Venkateswarluen_US
dc.contributor.authorKannanganat, Sunilen_US
dc.contributor.authorGangadhara, Sailajaen_US
dc.contributor.authorNabi, Rafiqen_US
dc.contributor.authorKozlowski, Pamela A.en_US
dc.contributor.authorMontefiori, David C.en_US
dc.contributor.authorLaBranche, Celia C.en_US
dc.contributor.authorWrammert, Jensen_US
dc.contributor.authorKeele, Brandon F.en_US
dc.contributor.authorBalachandran, Harikrishnanen_US
dc.contributor.authorSahu, Sujataen_US
dc.contributor.authorLifton, Michelleen_US
dc.contributor.authorSantra, Sampaen_US
dc.contributor.authorBasu, Rahulen_US
dc.contributor.authorMoss, Bernarden_US
dc.contributor.authorRobinson, Harriet L.en_US
dc.contributor.authorAmara, Rama Raoen_US
dc.date.accessioned2016-04-01T15:47:30Z
dc.date.issued2016en_US
dc.identifier.citationChamcha, V., S. Kannanganat, S. Gangadhara, R. Nabi, P. A. Kozlowski, D. C. Montefiori, C. C. LaBranche, et al. 2016. “Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine.” Open Forum Infectious Diseases 3 (1): ofw034. doi:10.1093/ofid/ofw034. http://dx.doi.org/10.1093/ofid/ofw034.en
dc.identifier.issn2328-8957en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:26318530
dc.description.abstractBackground. In this study, we analyzed the protective efficacy of a simian immunodeficiency virus (SIV) macaque 239 (SIVmac239) analogue of the clinically tested GOVX-B11 deoxyribonucleic acid (DNA)/modified vaccinia Ankara (MVA) human immunodeficiency virus vaccine. Methods. The tested vaccine used a DNA immunogen mutated to mimic the human vaccine and a regimen with DNA deliveries at weeks 0 and 8 and MVA deliveries at weeks 16 and 32. Twelve weekly rectal challenges with 0.3 animal infectious doses of SIV sootey mangabey E660 (SIVsmE660) were administered starting at 6 months after the last immunization. Results. Over the first 6 rectal exposures to SIVsmE660, <10-year-old tripartite motif-containing protein 5 (TRIM5)α-permissive rhesus macaques showed an 80% reduction in per-exposure risk of infection as opposed to a 46% reduction in animals over 10 years old; and, over the 12 challenges, they showed a 72% as opposed to a 10% reduction. Analyses of elicited immune responses suggested that higher antibody responses in the younger animals had played a role in protection. Conclusions. The simian analogue of the GOVX-B11 HIV provided strong protection against repeated rectal challenges in young adult macaques.en
dc.language.isoen_USen
dc.publisherOxford University Pressen
dc.relation.isversionofdoi:10.1093/ofid/ofw034en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800464/pdf/en
dash.licenseLAAen_US
dc.subjectage-dependent protectionen
dc.subjectantibodyen
dc.subjectDNA/MVA vaccineen
dc.subjectHIV vaccineen
dc.subjectSIVen
dc.titleStrong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccineen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalOpen Forum Infectious Diseasesen
dash.depositing.authorSantra, Sampaen_US
dc.date.available2016-04-01T15:47:30Z
dc.identifier.doi10.1093/ofid/ofw034*
dash.authorsorderedfalse
dash.contributor.affiliatedSantra, Sampa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record